The Shot That Heals Following a Heart Attack. Cardiologists at Texas A&M are developing a one-shot therapy that could help your heart recover during the weeks following a heart attack.
#HeartHealth #HeartAttackRecovery #MedicalBreakthrough #RNAtherapy #CardiologyResearchhttps://www.instagram.com/p/DW4joMAlrUw/
Howard G. Smith MD, AM on Instagram: "The Shot That Heals Following a Heart Attack
Cardiologists at Texas A&M are developing a one-shot therapy that could help your heart recover during the weeks following a heart attack.
The treatment uses self-amplifying RNA (saRNA), a technology similar to that used in some modern vaccines. After a simple injection into your arm muscle, your cells temporarily receive instructions to produce more of a natural heart-protective hormone called ANP.
Here’s why that helps:
• ANP helps reduce stress on the heart.
• It limits tissue damage and scarring.
• It supports healing during the critical recovery window.
Because the RNA instruction molecule copies itself, one injection keeps the ANP hormone circulating for several weeks, helping your heart repair itself during the most vulnerable and dangerous period.
Preclinical research shows self-amplifying RNA improves heart healing and protects vulnerable heart muscle after a heart attack. Critical human trials are still ahead. If they confirm these results, doctors could one day give one shot to help your heart recover more effectively following a heart attack.
References On My Website.
#HeartHealth #HeartAttackRecovery #MedicalBreakthrough #RNAtherapy #CardiologyResearch"
0 likes, 0 comments - drhowardsmithreports on April 8, 2026: "The Shot That Heals Following a Heart Attack
Cardiologists at Texas A&M are developing a one-shot therapy that could help your heart recover during the weeks following a heart attack.
The treatment uses self-amplifying RNA (saRNA), a technology similar to that used in some modern vaccines. After a simple injection into your arm muscle, your cells temporarily receive instructions to produce more of a natural heart-protective hormone called ANP.
Here’s why that helps:
• ANP helps reduce stress on the heart.
• It limits tissue damage and scarring.
• It supports healing during the critical recovery window.
Because the RNA instruction molecule copies itself, one injection keeps the ANP hormone circulating for several weeks, helping your heart repair itself during the most vulnerable and dangerous period.
Preclinical research shows self-amplifying RNA improves heart healing and protects vulnerable heart muscle after a heart attack. Critical human trials are still ahead. If they confirm these results, doctors could one day give one shot to help your heart recover more effectively following a heart attack.
References On My Website.
#HeartHealth #HeartAttackRecovery #MedicalBreakthrough #RNAtherapy #CardiologyResearch".
'Multimorbidity Patterns in Patients with Pulmonary Arterial Hypertension Identified Through Hospital Discharge Records: A Network-Based Analysis' - an article in Cardiovascular Innovations and Applications on #ScienceOpen:
🔗 https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2025.0008
🖇️ #CardiovascularMedicine #CardiologyResearch #Multimorbidity #NetworkMedicine
Multimorbidity Patterns in Patients with Pulmonary Arterial Hypertension Identified Through Hospital Discharge Records: A Network-Based Analysis
<div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section">
<a class="named-anchor" id="d7816681e172">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d7816681e173">Background:</h5>
<p dir="auto" id="d7816681e175">Considerable variability exists in the clinical presentations of pulmonary arterial
hypertension (PAH). Greater understanding of the comorbidities observed in Chinese
patients with PAH is urgently needed.
</p>
</div><div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section">
<a class="named-anchor" id="d7816681e177">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d7816681e178">Methods:</h5>
<p dir="auto" id="d7816681e180">This 10-year retrospective analysis was based on clinical data from hospital discharge
records for individuals diagnosed with PAH (n = 2584). We used propensity score matching
to match patients with PAH to individuals without a PAH diagnosis in a ratio of 1:1,
by age, sex, discharge time, and department, over the same period. We constructed
multimorbidity networks based on sex and age, and used the cosine index to measure
the co-occurrence of chronic diseases.
</p>
</div><div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section">
<a class="named-anchor" id="d7816681e182">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d7816681e183">Results:</h5>
<p dir="auto" id="d7816681e185">The mean numbers of comorbidities were 4.7 and 3.8 for patients with PAH and controls,
respectively. The main central and hub disorders were renal osteodystrophy, cardiovascular
illnesses, background retinopathy, diabetes mellitus, systemic lupus erythematosus,
epilepsy, and autoimmune hemolytic anemia. The average neighbor degree and closeness
were significantly smaller in the multimorbidity networks of patients with PAH than
control participants (Kolmogorov–Smirnov test, all P < 0.05).
</p>
</div><div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section">
<a class="named-anchor" id="d7816681e187">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d7816681e188">Conclusion:</h5>
<p dir="auto" id="d7816681e190">Our findings may aid in preventing comorbidities among patients with PAH and deepening
understanding of the underlying physiopathological mechanisms.
</p>
</div>
Howard Smith MD, AM
Mathrubhumi English
ScienceOpen